New stock news: Huada Beidou submits listing application to Hong Kong Stock Exchange.
According to the disclosure of the Hong Kong Stock Exchange on December 19th, Shenzhen Huada Beidou Technology Co., Ltd. (referred to as Huada Beidou) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CMB International and Ping An Securities (Hong Kong) acting as its joint sponsors.
According to the disclosure by Hong Kong Stock Exchange on December 19th, Shenzhen Huada Beidou Technology Co., Ltd. (referred to as Huada Beidou) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CICC and Ping An Securities (Hong Kong) as its joint sponsors. The prospectus shows that Huada Beidou is a provider of space positioning services, offering navigation positioning chips and modules that support Beidou and other major GNSS systems globally, while also providing GNSS-related solutions. According to the information from Zhishi Consulting, by 2024, in terms of shipment volume, the company ranks sixth in the global GNSS chip and module market with a market share of 4.8%. According to information from Zhishi Consulting, by 2024, in terms of revenue, the company ranks eighth globally and third among mainland Chinese companies in the GNSS chip and module market, with a market share of approximately 1.1%. The GNSS chip and module sub-market accounts for approximately 2.1% of the total revenue in the overall GNSS space positioning service market.
Related Articles

The innovative investigational radiopharmaceutical TLX591-CDx by GRAND PHARMA (00512) for diagnosing prostate cancer has successfully reached the main clinical endpoints in Phase III clinical trials in China.

Zhejiang Shibao (01057) A shares price fluctuation, no significant undisclosed information that should be disclosed.

Jiangxi Jdl Environmental Protection Co., Ltd. (688057.SH) plans to increase its capital by RMB 30 million to invest in Zhongke Hongtai.
The innovative investigational radiopharmaceutical TLX591-CDx by GRAND PHARMA (00512) for diagnosing prostate cancer has successfully reached the main clinical endpoints in Phase III clinical trials in China.

Zhejiang Shibao (01057) A shares price fluctuation, no significant undisclosed information that should be disclosed.

Jiangxi Jdl Environmental Protection Co., Ltd. (688057.SH) plans to increase its capital by RMB 30 million to invest in Zhongke Hongtai.






